PDS Biotechnology (NASDAQ:PDSB) Trading 9.1% Higher – Here’s What Happened

PDS Biotechnology Corporation (NASDAQ:PDSB)’s stock price shot up 9.1% on Tuesday . The company traded as high as $0.7349 and last traded at $0.69. 1,179,573 shares were traded during mid-day trading, an increase of 279% from the average session volume of 311,310 shares. The stock had previously closed at $0.6327.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. B. Riley Financial decreased their target price on shares of PDS Biotechnology from $5.00 to $3.00 and set a “buy” rating for the company in a research report on Tuesday, November 25th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PDS Biotechnology in a research report on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $9.00.

PDS Biotechnology Stock Down 3.8%

The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.09 and a current ratio of 2.09. The firm has a market cap of $32.74 million, a price-to-earnings ratio of -0.76 and a beta of 1.20. The business’s 50 day moving average price is $0.77 and its 200 day moving average price is $0.89.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Virtu Financial LLC acquired a new position in shares of PDS Biotechnology in the fourth quarter worth about $25,000. Watts Gwilliam & Co. LLC acquired a new stake in shares of PDS Biotechnology during the 2nd quarter valued at about $73,000. Tempus Wealth Planning LLC increased its stake in shares of PDS Biotechnology by 29.3% in the 4th quarter. Tempus Wealth Planning LLC now owns 61,800 shares of the company’s stock valued at $48,000 after purchasing an additional 14,000 shares in the last quarter. Marshall Wace LLP acquired a new position in PDS Biotechnology in the 2nd quarter worth about $91,000. Finally, Jane Street Group LLC acquired a new position in PDS Biotechnology in the 2nd quarter worth about $92,000. Hedge funds and other institutional investors own 26.84% of the company’s stock.

PDS Biotechnology Company Profile

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.